Skip to content

Skip to secondary menu

Jehovah’s Witnesses


Perioperative Care

Postoperative Anemia Management

Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial.

Khalafallah AA, Yan C, Al-Badri R, Robinson E, Kirkby BE, Ingram E, Gray Z, Khelgi V, Robertson IK, Kirkby BP

Source‎: Lancet Haematol 2016;3(9):e415-25.

Indexed‎: PubMed 27570088

DOI‎: 10.1016/S2352-3026(16)30078-3

Severe acute anemia after liver transplantation in an elderly Jehovah's Witness treated with high-dose erythropoietin and ferric carboxymaltose: a case report.

Brunetta DM, Kaufman J, De Santis GC, Mesquita DF, Souza FN, Garcia JH

Source‎: Transplant Proc 2015;47(8):2548-51.

Indexed‎: PubMed 26518969

DOI‎: 10.1016/j.transproceed.2015.09.014

Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery.

Ranucci M, Baryshnikova E, Crapelli GB, Rahe-Meyer N, Menicanti L, Frigiola A; Surgical Clinical Outcome REsearch (SCORE) Group.

Source‎: J Am Heart Assoc 2015;4(6):e002066.

Indexed‎: PubMed 26037084

DOI‎: 10.1161/JAHA.115.002066

Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial.

Corwin HL, Gettinger A, Rodriguez RM, Pearl RG, Gubler KD, Enny C, Colton T, Corwin MJ.

Source‎: Crit Care Med 1999;27(11):2346-50.

Indexed‎: PubMed 10579246

How do we treat life-threatening anemia in a Jehovah's Witness patient?

Posluszny JA Jr, Napolitano LM.

Source‎: Transfusion 2014;54(12):3026-34.

Indexed‎: PubMed 25330835

DOI‎: 10.1111/trf.12888

Transfusion-free management of gastrointestinal bleeding: the experience of a Bloodless Institute.

Sharma P, Barajas FJ, Krishnamoorthy P, Campo LM, Blumenthal E, Spinnell M.

Source‎: J Clin Gastroenterol 2015;49(3):206-11.

Indexed‎: PubMed 25144897

DOI‎: 10.1097/MCG.0000000000000200

Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis.

Mesgarpour B, Heidinger BH, Schwameis M, Kienbacher C, Walsh C, Schmitz S, Herkner H.

Source‎: Intensive Care Med 2013;39(11):1896-908.

Indexed‎: PubMed 23928897

DOI‎: 10.1007/s00134-013-3030-9

Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses.

Ball AM, Winstead PS.

Source‎: Pharmacotherapy 2008;28(11):1383-90.

Indexed‎: PubMed 18956998

DOI‎: 10.1592/phco.28.11.1383

Recombinant human erythropoietin in severe anaemia: issues of dosing and duration.

Charles A, Purtill M, Napolitano LM.

Source‎: Anaesth Intensive Care 2006;34(6):793-6.

Indexed‎: PubMed 17183900

The role of erythropoietin therapy in the critically ill.

Corwin HL.

Source‎: Transfus Med Rev 2006;20(1):27-33.

Indexed‎: PubMed 16373185

Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317].

Georgopoulos D, Matamis D, Routsi C, Michalopoulos A, Maggina N, Dimopoulos G, Zakynthinos E, Nakos G, Thomopoulos G, Mandragos K, Maniatis A; Critical Care Clinical Trials Greek Group.

Source‎: Crit Care 2005;9(5):R508-15.

Indexed‎: PubMed 16277712

Recombinant human erythropoietin use in a critically ill Jehovah's Witness after cardiac surgery.

Price S, Pepper JR, Jaggar SI.

Source‎: Anesth Analg 2005;101(2):325-7.

Indexed‎: PubMed 16037136

Life-threatening postoperative blood loss in a Jehovah's Witness, treated with high-dose erythropoietin.

Schälte G, Janz H, Busse J, Jovanovic V, Rossaint R, Kuhlen R.

Source‎: Br J Anaesth 2005;94(4):442-4.

Indexed‎: PubMed 15653706

The medical section of is designed as an informational resource primarily for use by clinicians and other health-care professionals. It provides neither medical advice nor treatment recommendations and does not substitute for an appropriately qualified health-care provider. The clinical literature cited is not published by Jehovah’s Witnesses, but it outlines transfusion-alternative strategies that might be considered. It is the responsibility of each qualified health-care provider to maintain awareness of new information, discuss options for care, and assist patients in making choices in accord with their medical condition, wishes, values, and beliefs. Not all listed strategies are appropriate or acceptable to all patients.

Patients: Always seek the advice of your doctor or other qualified health-care provider regarding medical conditions or treatments. Check with a doctor if you suspect you are ill.

The use of this website is governed by its terms of use.